Pages that link to "Q36919975"
Jump to navigation
Jump to search
The following pages link to Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders (Q36919975):
Displaying 50 items.
- JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin (Q24318979) (← links)
- Regulation of chromatin by histone modifications (Q24635070) (← links)
- Personalized medicine in gastric cancer: Where are we and where are we going? (Q26774521) (← links)
- Targeting the tumor microenvironment: JAK-STAT3 signaling (Q26825658) (← links)
- Genomic profiling of B-progenitor acute lymphoblastic leukemia (Q26829976) (← links)
- Janus kinase inhibitors in autoimmune diseases (Q26865446) (← links)
- JAK2 activation by growth hormone and other cytokines (Q27003058) (← links)
- Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion (Q27317353) (← links)
- AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines (Q27851932) (← links)
- Epstein-Barr virus-positive gastric cancer: a distinct molecular subtype of the disease? (Q28075698) (← links)
- CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients (Q28238474) (← links)
- Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor (Q28482297) (← links)
- Novel multiplexed assay for identifying SH2 domain antagonists of STAT family proteins (Q28535402) (← links)
- Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis (Q28674280) (← links)
- Mouse models of myeloproliferative neoplasms: JAK of all grades (Q28744478) (← links)
- ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells (Q28754852) (← links)
- Detection of mutations in myeloid malignancies through paired-sample analysis of microdroplet-PCR deep sequencing data. (Q30836256) (← links)
- Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase (Q33390032) (← links)
- Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities (Q33396730) (← links)
- Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera (Q33398180) (← links)
- Comparative analysis of the JAK/STAT signaling through erythropoietin receptor and thrombopoietin receptor using a systems approach (Q33407887) (← links)
- Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice (Q33419130) (← links)
- A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis (Q33434284) (← links)
- Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study (Q33437373) (← links)
- DC - SIGNR by influencing the lncRNA HNRNPKP2 upregulates the expression of CXCR4 in gastric cancer liver metastasis (Q33560349) (← links)
- Defining the blueprint of the cancer genome (Q33671802) (← links)
- ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia (Q33687080) (← links)
- Endogenous retrovirus induces leukemia in a xenograft mouse model for primary myelofibrosis. (Q33767496) (← links)
- Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms (Q33771667) (← links)
- Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis (Q33788714) (← links)
- Detection of exon 12 Mutations in the JAK2 gene: enhanced analytical sensitivity using clamped PCR and nucleotide sequencing (Q33813824) (← links)
- Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis (Q33886243) (← links)
- Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms (Q33982315) (← links)
- Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors (Q33982322) (← links)
- c-Abl activates janus kinase 2 in normal hematopoietic cells (Q33985308) (← links)
- DNA damage stress and inhibition of Jak2-V617F cause its degradation and synergistically induce apoptosis through activation of GSK3β (Q34075662) (← links)
- MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. (Q34120830) (← links)
- Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation (Q34124973) (← links)
- Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways (Q34147910) (← links)
- HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans (Q34162151) (← links)
- Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). (Q34169114) (← links)
- A mathematical framework to determine the temporal sequence of somatic genetic events in cancer (Q34200279) (← links)
- Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3). (Q34270442) (← links)
- JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation. (Q34293019) (← links)
- The constitutive activation of Jak2-V617F is mediated by a π stacking mechanism involving phenylalanines 595 and 617. (Q34316190) (← links)
- The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders (Q34349150) (← links)
- Relevance of JAK2V617F positivity to hematological diseases--survey of samples from a clinical genetics laboratory (Q34547493) (← links)
- mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms (Q34575726) (← links)
- The JAK2 V617F somatic mutation, mortality and cancer risk in the general population (Q34612649) (← links)
- Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure (Q34671755) (← links)